Based in the United States, Delve Bio is a startup.
Delve Bio develops a metagenomic next-generation sequencing (mNGS) diagnostic test called Delve Detect that rapidly identifies bacteria, viruses, fungi, and parasites in cerebrospinal fluid to diagnose central nervous system infections such as meningitis and encephalitis.
Funding rounds, investor list, risk signals, and comparable startups, all gated to subscribers.